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Abstract
Bidirectional cross-talk between the neuroendocrine and
immune systems orchestrates immune responses in both physi-
ologic and pathologic settings. In this study, we provide in vivo
evidence of a critical role for the thyroid hormone triiodothyro-
nine (T3) in controlling the maturation and antitumor functions
of dendritic cells (DC). We used a thyroid hormone receptor
(TR) b mutant mouse (TRbPV) to establish the relevance of the
T3-TRb system in vivo. In this model, TRb signaling endowed
DCs with the ability to stimulate antigen-speciﬁc cytotoxic
T-cell responses during tumor development. T3 binding to TRb
increased DC viability and augmented DC migration to lymph
nodes.Moreover, T3 stimulated the ability ofDCs to cross-present
antigens and to stimulate cytotoxic T-cell responses. In a B16-OVA
mouse model of melanoma, vaccination with T3-stimulated
DCs inhibited tumor growth and prolonged host survival, in part
by promoting the generation of IFNg-producing CD8þ T cells.
Overall, our results establish an adjuvant effect of T3-TRb signal-
ing in DCs, suggesting an immediately translatable method
to empower DC vaccination approaches for cancer immuno-
therapy. Cancer Res; 75(7); 1265–74. 2015 AACR.
Introduction
Reciprocal regulation of neuroendocrine and immune sys-
tems preserves homeostasis and orchestrates coordinated
responses in physiologic and pathologic settings. The attribute
of sharing common ligands (hormones and cytokines) and
receptors between these two systems allows bidirectional com-
munication and offers additional opportunities for therapeutic
intervention (1).
Thyroid hormones are critical regulators of cellular differenti-
ation, growth, and metabolism in virtually all tissues. Cellular
activity of thyroid hormone is usually classiﬁed as genomic
(nuclear) and nongenomic (initiated either in the cytoplasm or
at the plasma membrane). The genomic mechanism of thyroid
hormone action requires the participation of active thyroid hor-
mone: triiodothyronine (T3) and its nuclear receptors (TR). TRs
are codiﬁedbyTRA andTRB genes that are expressed in fourmajor
isoforms: TRa1, TRb1, TRb2, and TRb3, whereas other non-T3
binding isoforms are also expressed. In addition, nongenomic
actions of thyroid hormone have also been recognized (2).
Several transgenic mouse models expressing TR mutants have
been developed to understand whether TR isoforms can mediate
speciﬁc functions in vivo (3–5). In particular, TRbmutant knock-in
mice harboring a frame-shift mutation in the last 14 carboxyl-
terminal amino acids of TRb1 (TRbPV) have been generated (3).
The TRbPV mutation was initially identiﬁed in a patient bearing
the syndrome of thyroid hormone resistance. In vitro character-
ization of PVmutant showed the complete loss of T3-binding and
transactivation activities, interfering also with wild-type TR activ-
ity (6). TRbPV, as well as other mouse models, has enabled the
demonstration that TRs could function as tumor suppressors,
revealing how loss of normal functions of TRs either by deletion
or by mutation contributes to cancer development, progression,
and metastasis (7).
Dendritic cells (DC) are specialized innate immune cells
endowed with a unique capacity to orchestrate adaptive immu-
nity. These cells are the main antigen-presenting cells (APC) that
recognize, process, and present antigens to na€ve T cells for the
induction of antigen-speciﬁc immune responses. The recognition
of lipopolysaccharide (LPS) or other non-self antigens promotes
DC maturation through pattern recognition receptors. Matured
DCs alter the expression of chemokine receptors andmigrate to T-
cell zones in secondary lymphoid organs where they present
antigens to na€ve T cells (8).Na€veCD8þT cells are then instructed
to proliferate and mount cytotoxic T-cell responses. Interestingly,
APC can process exogenous antigens and present them in
the context of MHC-I molecules, a process termed "cross-
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presentation" that is crucial for the induction of protective immu-
nity against viruses and tumors (9).
DC-based cancer immunotherapeutic strategies have been
widely used to engender CD8þ T-cell responses using patients'
own DCs loaded with tumor-associated antigens ex vivo (10).
However, the success is frequently limited as activated DCs have a
short half-life in lymph nodes, and antigen processing and pre-
sentation from dead DCs may induce T-cell tolerance. Therefore,
increasing DC survival and immunogenicity represents a major
challenge in vaccination strategies (11). Interestingly, increased
phosphorylation of Akt has been shown to enhance DC survival
and potentiate DC-based immunotherapy (12).
The direct effects of thyroid hormone on T cells, via either
genomic or nongenomic mechanisms, have been studied by
many authors (13, 14) in both primary T lymphocytes and
lymphoma T-cell lines. However, studies on the impact of thyroid
hormone in the initiation of adaptive immune responses are just
emerging. We showed that expression of TRs, mainly the b1
isoform, contributes to DC maturation and Th1-type cytokine
secretion induced by physiologic levels of T3 (15). Mechanisti-
cally, this effect involved activation of Akt and NF-kB pathways
(16) and was counteracted by glucocorticoids (17).
In this study, we investigated in TRbPVmice the involvement of
TRb in T3-induced modulation of DC function. Particularly, we
examined the impact of T3-TRb signaling in in vivo cytotoxicity
and in vitro antigen cross-presentation. Finally, we studied the
effects of T3 in antigen-speciﬁc DC-based immunotherapy in the
B16 melanoma model.
Materials and Methods
Mice
Wild-type (WT) female C57BL/6 mice (B6; H-2b) were
obtained from Ezeiza Atomic Center (Argentina). Homozygous
TRbPV C57BL/6 mutant mice (TRbPV) were obtained and geno-
typed as described (6). Mice were maintained under speciﬁc
pathogen-free conditions and used at 6 to 10 weeks old. Animal
protocols were in compliance with theGuide for the Care andUse
of Laboratory Animals published by the NIH and the local
institutional animal care committee.
Cell preparation and culture
Immature bone marrow dendritic cells (iDC) were obtained
from C57BL/6 WT or TRbPV mice as described (15). For primary
DCs, spleens and lymphnodeswere incubatedwith collagenaseD
and then mashed through a cell strainer. DCs were sorted as
described (18) into F4/80 CD11bþ CD11cþ B220 MHC-IIþ
LY6C conventional DCs (eBioscience). iDCs were cultured with
T3 (5 nmol/L; Sigma) or LPS (100 ng/mL; E coli strain 0111:B4;
Sigma) for 18 hours. Parallel cultures were maintained without
stimuli as controls. T3 was prepared according to the manufac-
turer's recommended protocol. To rule out endotoxin contami-
nation of the T3 preparation, we checked endotoxin content that
raised levels lower than 0.03 IU/mL (limit of detection) by the
Limulus amebocyte lysate assay (Sigma).
Flow cytometric analysis of DC phenotype
DCs were washed with PBS supplemented with 2% (vol/vol)
FCSand resuspended in10%(vol/vol) FCS inPBS.Cellswere then
incubated for 30minutes at 4Cwith the followingﬂuorochrome-
conjugated mAbs: FITC–anti-CD11c, phycoerythrin (PE)–anti-
IA/IE (MHC-II), PE–anti-CD40, PE–anti-CD80, PE–anti-CD86,
and PECy7–anti-CCR7 (BD Biosciences PharMingen). Cells were
processed and analyzed in a FACS Canto II ﬂow cytometer (BD
Biosciences) using FlowJo software (Tree Star).
Cytokine determination
Intracellular cytokine detection was assessed by ﬂow cytometry
as described (15) using PE-conjugated anti-IL12 mAb (BD Bio-
sciences). IL10 and IFNg detection was performed in
culture supernatants using standard capture ELISA (BD Bio-
sciences; ref. 15).
Allogeneic T-cell cultures
Allogeneic T-cell cultures were performed as described (15).
Brieﬂy, allogeneic splenocytes (BALB/c, 1  105 cells/well, re-
sponder cells) were stained with carboxyﬂuorescein diacetate
succinimidyl ester (CFSE, 5 mmol/L) at 37C for 15 minutes.
Labeled cells were incubated for 3 days with irradiated DCs
(1:15, DC:splenocytes). Cells were analyzed by FACS gating
on CFSE-labeled cells to assess allogeneic T-cell proliferation
induced by DCs.
Protein extraction and Western blotting
Protein extracts were obtained as described (15). Phospho-
Akt (5473), Bcl-2 (50E3), and GAPDH (D16H11) rabbit
monoclonal Abs were from Cell Signaling Technology, Inc.
Western blot was performed as described (17).
In vivo cytotoxic assays
Cytotoxic assays were conducted as described (19). Mice were
i.v. immunized with 5  106 DCs incubated for 18 hours
with: (i) PBS (control), (ii) ovalbumin (OVA;100 mg/mL;
Worthington), (iii) OVAþLPS (100 ng/mL), or (iv) OVAþT3
(5 nmol/L). Spleen cells from syngeneic mice were labeled with
either 3 mmol/L CFSE (CFSEhigh) or 0.5 mmol/L CFSE (CFSElow) in
Hank's Balanced Salt Solution and then washed in Hank's Bal-
anced Salt Solution 10% FCS. CFSEhigh cells were pulsed with
OVA257–264 peptide (10 ng/mL; Sigma) for 30 minutes at 37C.
CFSElow cells were not pulsed and served as an internal control.
On day 7 after immunization, mice were injected i.v. with a
mixture of 3  106 CFSElow and 3  106 CFSEhigh cells. Spleen
cells were analyzed by ﬂow cytometry 24 hours later.
Antigen cross-presentation assay
This assay was conducted as described (20). Brieﬂy, DCs
were incubated for 4 hours with (i) PBS (control), (ii) OVA
(100 mg/mL), (iii) OVA257–264 (10 ng/mL), or (iv) OVAþT3
(5 nmol/L). Besides, B3Z T hybridoma cells [which express LacZ
upon binding of the T-cell receptor (TCR) to OVA257–264/Kb
complex] were placed at different effector/target cell ratios. After
coincubation of DCs with B3Z T hybridoma cells overnight,
they were lysed by addition of 125 mL of a solution containing
5 mmol/L o-nitrophenyl-p-D-galactoside (ONPG) in PBS/0.5%
NP-40. After 4-hour incubation at 37C, the amount of LacZ
enzyme was quantiﬁed by the hydrolysis of ONPG, measuring
optical density (OD) at 415 nm.
Cell death assays
After DC treatment with dexamethasone (10 mmol/L; Sigma)
and/or T3 (5 nmol/L) for 18 hours, cell death was evaluated by
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ﬂow cytometry using the FITC–Annexin V binding assay and 7-
aminoactinomycin D (7-AAD; BD Biosciences) as described (17).
DC migration in vivo
Control and T3-stimulated DCs labeled with CFSE (5 mmol/L)
were injected s.c. into mice. Lymph node DC-CFSEþ cells were
analyzed by ﬂow cytometry 24, 48, and 72 hours later.
RNA extraction and reverse transcription/qPCR
Total RNA isolation and cDNA synthesis were performed as
described (16). qPCR analysis was carried out using an ABI
Prism 7500 detection system (Applied Biosystems) and SYBR
Green chemistry as described (16). Gene-speciﬁc primer sets were
as follows: 50-GGCTCTCCTTGTCATTTTCCAG-30 (CCR7 for-
ward), 50-AATACATGAGAGGCAGGAACCAG-30 (CCR7 reverse),
50-GGCACCACACTTTCTACAATG-30 (b-actin forward) and 50-
TGGCTGGGGTGTTGAAGGT-30 (b-actin reverse). To determine
relative changes in CCR7 gene expression, the 2DDCt method was
used and normalized against the housekeeping gene b-actin as
internal control. All primers were from Sigma-Genosys.
B16-OVA tumor model
The syngeneic melanoma B16.F1-OVA line (gift from Dr.
Dellabona, Fondazione Centro San Raffaele del Monte Tabor-
San Raffaele Scientiﬁc Institute, Milan, Italy) was used (21). Cells
were passaged every 2 to 3 days, and growing cultureswere used to
generate tumors. For tumor induction, 2 104 B16.F1-OVA cells
were administered s.c. in 250 mL PBS in the left ﬂank of C57BL/6
mice. Animals were monitored for tumor growth by palpation,
and tumor size was measured every 2 to 3 days with a caliper
(tumor volume ¼ L W2/2, where L ¼ length and W ¼ width).
Animal survival was deﬁned as the time between tumor cell
inoculation and the day of sacriﬁce (tumor diameter, 20 mm;
ref. 22).
DC-based immunotherapeutic protocol
DCs were treated with OVA (100 mg/mL, DCþOVA), OVA and
T3 (5 nmol/L, DCþOVAþT3), or PBS (control). Treated DCs (1.5
 106) were injected s.c. on the contralateral ﬂank of tumor-
bearing mice at days 1, 3, 5, and 8 after tumor cell (B16.F1-OVA)
inoculation.
Analysis of tumor-inﬁltrating cells
Tumors were removed and single-cell suspensions were pre-
pared by enzymatic digestion and submitted to Ficoll–Hypaque
(Sigma) gradient centrifugation as described (23). Immune cell
populations (CD8, CD4, and NK) were determined by ﬂow
cytometry by incubating with PECy5–anti-CD4, PE–anti-CD8,
and FITC–anti-NK1.1 mAbs (BD Biosciences). Cells were then
analyzed in a FACS Canto II ﬂow cytometer (BD Biosciences)
using FlowJo software (Tree Star).
Cytokine production
Ten days after the last DC transfer, splenocytes were stimulated
withOVA257–264. After 72hours, IFNg secretedby tumor-speciﬁc T
cells was determined by ELISA (BD Biosciences). Intracellular
IFNg was determined by ﬂow cytometry (15).
Statistical analysis
Analysis of intergroup differences was conducted by one-way
ANOVA, followed by the Student–Newman–Keuls test. Survival
differences and rates of tumor establishment were compared
using the Gehan–Breslow–Wilcoxon test. P values less than
0.05 were considered statistically signiﬁcant. All experiments
were performed at least in triplicate.
Results
Binding of T3 to TRb promotes DC maturation and function
in vivo
To elucidate the pathophysiologic relevance of the TRb1
in vivo, we evaluated the effects of T3 action in the maturation
and function of bone marrow–derived DCs from TRbPV mice.
For this purpose, DCs from WT (DCWT) and homozygous
TRbPV (DCPV) mice were exposed to T3 and analyzed for the
expression of MHC-II and costimulatory molecules, as well as
for IL12 and IL10 production. Whereas T3 promoted matura-
tion of DCWT (15), as revealed by increased expression of MHC-
II, CD40, CD80, and CD86 on the surface of these cells, DCPV
exhibited a prominent immature phenotype characterized by
marked expression of CD11c, and lower expression of matu-
ration markers (Fig. 1A, left and right plots). Moreover, the
immature phenotype of DCPV was associated with a reduced
DC functionality as T3 could not increase the frequency of IL12-
producing DCPV when compared with T3-stimulated DCWT
(Fig. 1B).
The prominent immature phenotype of T3-conditoned DCPV
prompted us to investigate the T-cell allostimulatory capacity of
these cells. In contrast with T3-matured DCWT (15), T3-condi-
tioned DCPV did not increase the proliferation of BALB/c
(H-2d) splenocytes (Fig. 1C). The poor allostimulatory capacity
was also reﬂected by diminished frequency of IFNg-producing
T cells and reduced IFNg secretion (Fig. 1D and E, respectively).
These results were comparable with those observed in DCs
isolated from lymph nodes and spleens from WT and TRbPV
mice (Fig. 1F and G, respectively). In addition, lymph node
cells but not splenocytes from TRbPV mice showed higher
IL10 secretion when compared with WT mice. Interestingly,
whereas T3 induced AktSer-473 phosphorylation after 30 min-
utes in T3-stimulated DCWT (16), this effect was abrogated in
DCPV (Fig. 1H). Taken together, these results highlight the
critical role of intact TRb expression in the control of DC
signaling and function in vivo.
T3 instructs DCs to stimulate cytotoxic T-cell responses
We previously reported the ability of T3 to induce amature DC
phenotype capable of skewing the balance toward a dominant
Th1 proﬁle (15), which might inﬂuence the development of
cytotoxic T-cell responses. However, T3 failed to exert this effect
in DCs from TRbPV mice (Fig. 1), a mutation linked to cancer
development (7). Taken together, these evidences prompted us
to ascertain the role of T3 in cancer by assessing the ability of
T3-stimulated DCs to modulate antigen-speciﬁc T-cell cytotoxic-
ity in in vivo cytotoxicity assays.
Control and OVA-stimulated DCs failed to mount a robust
cytotoxic-speciﬁc response (similar CFSEhigh/CFSElow proﬁle,
mean cytotoxic activity: 37.95%; Fig. 2A and B). However,
immunization with OVA-pulsed T3-stimulated DCs resulted
in activation of OVA-speciﬁc cytotoxic responses capable of
clearing OVA257–264 peptide-coated splenocytes (mean cyto-
toxic activity: 87.41%) similar to the positive control group
(LPS, mean cytotoxic activity: 100.00%; ref. 24). These results
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show the capacity of T3-matured DCs to trigger antigen-speciﬁc
cytotoxic responses in vivo.
As antigen cross-presentation is essential for mounting cyto-
toxic T-cell responses against tumors (9), the implications of
the T3-TRb signaling in this process were assessed. We used B3Z
T hybridoma cells, which express LacZ upon binding of TCR
recognizing the OVA peptide presented in the context of MHC-
I. As shown in Fig. 2C, OVA-pulsed T3-stimulated DCs signif-
icantly increased b-Gal activity when compared with OVA-
pulsed or unpulsed DCs at all B3Z:DC ratios analyzed. This
T3-mediated effect was comparable with that induced by
OVA257–264 (a positive control), suggesting modulation of
cross-presentation by T3 signaling.
T3 modulates DC viability
Apoptosis of DCs is a key event in the control of
tolerance versus immunity and has been documented in
several types of solid and blood cancers (25–27). As induction
of apoptosis favors the establishment of immunosuppres-
sive microenvironments characterized by the differentiation
Figure 1.
Role of TRb signaling in T3-induced DC maturation and function in vivo. DCWT and DCPV were treated with T3 or left untreated and analyzed as described.
A, ﬂow cytometry analysis of phenotypic markers. Histograms are gated on CD11cþ cells (left plot). Dotted histograms, nonspeciﬁc binding determined
with isotype-matched control antibodies (IC); gray histograms, control DC phenotypic markers; black histograms, T3-stimulated DC phenotypic
markers. Results are expressed as mean ﬂuorescence intensity (MFI) within the CD11cþ population (right plot). B, intracytoplasmic detection of IL12p70.
Values are given as the percentage of total CD11cþ IL12-producing cells. C–E, allostimulatory capacity of DCs. C, proliferation of allogeneic splenic
T cells was determined by CFSE dilution. Continuous and dotted lines represent proliferation of allogeneic splenic T cells cultured with DCWT and DCPV,
respectively. D and E, IFNg production was evaluated by ﬂow cytometry and ELISA, respectively. F and G, IFNg and IL10 production in allogeneic T cell cultures
were measured by ELISA. H, Akt phosphorylation in DCs was evaluated by Western blot. Data are expressed as mean  SD and are from a representative
of three experiments.  , P < 0.05;  , P < 0.001 vs. control DCWT; #, P < 0.05 vs. T3-stimulated DCWT.
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of T regulatory cells and impairment of DC functionality
(28), we evaluated the effect of T3 on DC survival. Cell death
was assessed in DCs treated or not with T3 or dexamethasone,
a typical proapoptotic stimulus (29). As shown in Fig. 3A
and B, T3 decreased the number of apoptotic (Annexin
Vþ/7-AAD) and necrotic (Annexin Vþ/7-AADþ) cells com-
pared with control DCs. Moreover, T3 counteracted the known
proapoptotic effect of dexamethasone in DCs. After 30 min-
utes of stimulation, T3 increased the expression of Bcl-2 (30),
an effect that persisted even after 18 hours (Fig. 3C). Inter-
estingly, T3-induced Bcl-2 upregulation correlated with
increased DC survival (Fig. 3A and B). Thus, exposure to T3
increases DC resistance to apoptosis, an effect that may extend
DC lifespan.
T3 enhances the migratory capacity of DCs to lymph nodes
To elicit a primary immune response, DCs migrate to
lymph nodes where they reach T cells for activation (31).
We evaluated the ability of T3 to induce DC migration to
lymph nodes by tracking CFSE-labeled DCs (CFSEþ/CD11cþ)
by ﬂow cytometry. Although the percentage of double-posi-
tive DCs in lymph nodes was low when they were not exposed
to T3, it was signiﬁcantly enhanced in T3-treated DCs
(Fig. 4A). In turn, a time-course experiment showed that DC
migration was increased in response to T3 after 72 hours of
injection, but it was not different at 24 and 48 hours (DC-T3
vs. DC; Fig. 4B).
Migration of DCs to secondary lymphoid organs and tissues
relies on a cascade of discrete events, including regulation of
chemokines and their speciﬁc receptors (32). As CCR7 has an
essential role in DC homing to lymph nodes (33), CCR7 expres-
sion was determined in T3-stimulated DCs. Exposure to T3
resulted in a signiﬁcant increase in CCR7 protein (Fig. 4C and
D) andmRNA (Fig. 4E) to levels comparablewith positive control
(LPS; ref. 34).
T3-stimulated DCs instruct the development of CD8þ T-cell–
mediated responses
To further assess the role of T3-stimulated DCs on tumor
immunity, we investigated whether T3 may enhance the
therapeutic potential of DC vaccines in vivo. We establish-
ed a mouse model of B16-OVA melanoma (B16 cells in
which OVA was stably expressed to allow monitoring of
antigen-speciﬁc responses). We treated mice with T3-stimu-
lated DCs in the presence of tumor antigen (OVA; Fig. 5A).
Mice immunized with T3-stimulated DCs plus OVA showed a
signiﬁcant delay in tumor onset (Fig. 5B), as well as a sub-
stantial decrease in tumor size measured at day 27 (Fig. 5C).
In turn, s.c. administration of T3-stimulated DCs (þOVAþT3)
resulted in prolonged mice survival compared with DCþOVA
(Fig. 5D): 60% DCþOVAþT3 versus 20% DCþOVA at 40
days after tumor inoculation. Of note, all saline-treated
mice died within 40 days after the B16-OVA implantation.
Accordingly, there was a higher number of tumor-free mice
when they were injected with T3-pulsed DCs (þOVAþT3)
compared with mice receiving untreated DCs (þOVA) or
controls (Fig. 5E).
T3-stimulated DCs increase the number of tumor-inﬁltrating
CD8þ T cells and augment IFNg-producing antigen-speciﬁc
immune responses
To further investigate the effect of T3 on DC-mediated
antitumor responses, we evaluated the number of tumor-inﬁl-
trating T cells by ﬂow cytometry. Flow cytometric analysis
revealed an increased number of inﬁltrating intratumoral
CD8þ T cells in mice receiving DCþOVAþT3 compared with
DCþOVA (Fig. 6A). However, we could ﬁnd no signiﬁcant
differences when comparing CD4þ T cells (Fig. 6A) and NK cells
(data not shown) between the experimental groups analyzed.
Thus, T3 endows DCs with the ability to augment a cytotoxic
T-cell response that restrains tumor growth in vivo.
Figure 2.
T3 increases the ability of DCs to
stimulate antigen-speciﬁc cytotoxic
T-cell responses and antigen cross-
presentation. In vivo cytotoxicity
(A and B) and in vitro antigen cross-
presentation (C) assays were
performed as described. A, density
graphs represent the amount of CFSE-
labeled cells. Number in each plot
indicates the percentage of
CFSElow and CFSEhigh cells. B,
cytotoxic activity was determined by
calculating the percentage of speciﬁc
lysis of peptide-pulsed CFSEhigh cells
following the formula: 100–
(percentage of peptide pulsed/
percentage of unpulsed in immunized
mice)/(percentage of peptide pulsed/
percentage of unpulsed in control
mice)  100). C, OD at 415 nm in each
experimental group is shown. Data
are expressed as mean  SD and are
from a representative of three
experiments.  , P < 0.01;  , P < 0.001
vs. DCþOVA.
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As T3-conditioned DCs induced prolonged survival and
intratumoral CD8þ T-cell inﬁltration in mice bearing B16-OVA
tumors, we aimed at evaluating whether a systemic tumor-
speciﬁc immune response was induced by T3-stimulated DCs.
Figure 3.
T3 increases DC viability. iDCs were treated with T3, Dex, or left
untreated. A and B, DC viability was assessed as described. Cells were
gated on CD11cþ cells, and Annexin V and 7-AAD were analyzed. A,
numbers represent the percentage of cells in each quadrant. Cells in
early phases of apoptosis were Annexin Vþ/7-AAD and late-stage
apoptotic and necrotic cells were Annexin Vþ/7-AADþ. B, values are
given as the percentage of apoptotic and necrotic cells within total
CD11cþ cells. Data are expressed as mean  SD and are from a
representative of three experiments;  , P < 0.001 vs. apoptotic and
necrotic control DCs, respectively; #, P < 0.001 vs. apoptotic and
necrotic Dex-DCs, respectively. C, analysis of Bcl-2 by Western blot.
Bottom, same blot probed for GADPH to check for equal loading.
Representative of three experiments.
Figure 4.
T3 increases themigratory capacity of DCs to lymph nodes. iDCswere treated
with T3, LPS, or left untreated. A and B, migration of DCs in vivo was
determined as described in Materials and Methods. A, cell migration to lymph
nodes after 72 hours. Numbers represent the percentage of cells in each
quadrant. B, time-course study of migration of CD11cþ/CFSEþ cells to lymph
nodes (24, 48, and 72 hours). Values are given as the percentage of
CD11cþ/CFSEþ cells of total lymph nodes cells. C–E, CCR7 expression was
analyzed by ﬂow cytometry (C and D) and qPCR (E). C, representative
histograms of three independent experiments are gated on CD11cþ cells.
Black histograms, nonspeciﬁc binding determined with isotype-matched
control antibodies; white histograms, CCR7. D, results are expressed as mean
ﬂuorescence intensity (MFI)within theCD11cþpopulation. Data are expressed
as mean SD and are from a representative of three experiments; #, P < 0.05
vs. DC 72 h and DCþT3 48 h;  , P < 0.05;  , P < 0.001 vs. DC.
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Secretion of IFNg was signiﬁcantly higher in splenic T cells
derived from mice injected with DCþOVAþT3 compared with
mice treated with DCþOVA in the absence of T3 (Fig. 6B, white
boxes). Notably, when T cells from mice treated with T3-
stimulated DCs were restimulated with OVA257–264 (Fig. 6B,
black boxes), a 3-fold increase in IFNg secretion was registered
(DCþOVAþT3 vs. DCþOVA), indicating an antigen-speciﬁc
antitumor T-cell response. By intracellular staining, we found
that IFNg production was mainly restricted to CD8þ T cells
(Fig. 6C). Therefore, DCs exposed to T3 increase the frequency
of IFNg-secreting CD8þ T cells and bolster antigen-speciﬁc
antitumor T-cell responses.
Discussion
Biologic signals that control DC maturation and function can
ultimately tailor adaptive immune responses (8). Our study
highlights an alternative mechanism by which T3 contributes to
cancer progression by acting at the DC level and bolstering CD8þ
T-cell mediated antitumor responses.
In contrast with the reported effects induced by T3 on DCs
frommice with intact TRb1, the main TR isoform (15), T3 could
not trigger maturation effects on DCs from homozygous TRbPV
knock-in mice (DCPV). Interestingly, T3-treated DCPV showed a
deﬁcient T-cell allostimulatory capacity and impaired Akt acti-
vation when compared with DCWT (16). These ﬁndings high-
light a critical role of intact TRb expression in vivo in the control
of DC signaling and function as previously shown using small
interfering RNA silencing strategies (16). The well-known asso-
ciation of TRbPV with cancer development (7), together with
our previous observations indicating the promotion of a DC1
mature phenotype by T3 (15), suggested that manipulation of
the T3-TRb1 system on DCs could favor an IFNg-mediated
cytotoxic T-cell response and bolster antitumor immunother-
apeutic strategies.
DCs share unique features and plasticity that make them an
ideal choice for antitumor vaccines (35). DC-based vaccina-
tion strategies effectively evoke tumor-speciﬁc cytotoxic T-cell
responses, which contribute to restrain tumor progression
either alone or in combination with other immunotherapeu-
tic approaches, including blockade of negative regulatory
checkpoints such as CTLA-4 or PD-1/PD-L1 (36). However,
the overarching goal of cancer vaccinologists is to elicit long-
lasting tumor-speciﬁc CD8þ T cell-mediated responses that
are sufﬁciently robust to evoke durable tumor regression
and/or eradication. In particular, cross-presentation of antigen
is essential for induction of effective cytotoxic T-cell responses
against tumors (37). Our results demonstrate that T3 potenti-
ates DC function at multiple levels, including DC survival,
migration, and allostimulatory T-cell capacity. Moreover, it
instructs DCs to bolster antigen-speciﬁc cytotoxic responses in
vivo and antigen cross-presentation in vitro. These ﬁndings
further support the in vivo role of T3 in cancer biology. Further
studies are in progress to elucidate the impact of regulatory T-
cell responses elicited by T3-conditioned DCs in tumor and
inﬂammatory microenvironments.
In DC-based cancer immunotherapies, DCs are usually iso-
lated in vitro and loaded with tumor antigen. These antigen-
bearing DCs are then injected back into patients, migrate into
lymphoid tissues, and activate antigen-speciﬁc T cells for elim-
inating tumor cells. However, preservation of DC survival is a
current challenge (35). DC's short lifespan probably evolved to
prevent autoimmunity, but in the context of immunotherapy,
short-lived, ex vivo–modiﬁed DC vaccines will likely undergo
apoptosis before encountering and optimally activating tumor
antigen-reactive T-cell clones. Interestingly, it has been demon-
strated that immunization of mice with DCs infected with
a Bcl-xL–encoding adenovirus effectively generated more
potent antitumor immunity (38) and modulated Akt activa-
tion, which is a critical regulator of DC lifespan (12). Our
Figure 5.
T3-stimulated DCs in the presence of
tumor antigen induce potent
antitumor T-cell responses. A,
schematic representation of the
treatment of B16-OVAmelanomawith
control, OVA (DCþOVA), OVA, and T3
(DCþOVAþT3) DCs. B, tumor growth
kinetics. Data are expressed as mean
 SD;  , P < 0.05 vs. DCþOVA.
C, photographs of tumors removed on
day 27. D and E, Kaplan—Meier
analysis showing the percentages of
surviving mice (D) and tumor-free
mice (E) of each experimental group.
Results are from a representative of
three experiments (n ¼ 5).
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ﬁndings demonstrate the ability of T3 to increase DC survival
in accordance with our previous report, indicating an increase
in Akt phosphorylation in T3-stimulated DCs (16). These
results together with the modulation of Bcl-2 expression in
T3-conditioned DCs emphasize the potential role of T3 treat-
ment ex vivo as a powerful tool to increase the effectiveness of
DC-based vaccines.
CCR7 is a chemokine receptor that drives DC migration to
lymph nodes, inducing an increase in lymph node cellularity
even before the onset of T-cell proliferation (33, 39). It has been
reported that DC migration could be enhanced by preinjection
of inﬂammatory cytokines that augment the expression of
the CCR7 ligand, CCL21 (40). Here, we found that exposure
of DCs to T3 increases CCR7 expression and favors DC migra-
tion to lymph nodes, a critical event for T-cell encounter.
Interestingly, CCR7 expression has been shown to extend DC
survival through a mechanism involving Akt activation (41).
This report is in line with our ﬁndings showing sustained Akt
activation, increased CCR7 expression, and extension of DC
lifespan induced by T3.
The inﬂuence of T3 in DC function and maturation prompted
us to investigate the impact of T3-TRb complex in DC-mediated
T-cell activation and the development of antitumor responses
in a mouse B16-OVA tumor model (21). Vaccination with T3-
activated DCs in the presence of a tumor antigen (OVA) increased
the percentage of tumor-free mice, delayed the kinetics of
tumor growth, and improved mice survival. This vaccination
protocol resulted in prominent inﬁltration of CD8þ T cells
within the tumor. These ﬁndings are of particular interest, as
adoptive transfer of tumor-inﬁltrating lymphocytes leads to
potent antitumor responses, cancer regression, and prolonged
patient survival in a variety of tumor types (42, 43). Interest-
ingly, we found that T cells isolated from tumor-bearing mice
treated with T3-conditioned DCs displayed heightened IFNg
secretion and sustained CD8þ T-cell responses. In agreement,
therapeutic administration of DCs pulsed in vitro with the heat
shock protein 70 in the presence of a cyclooxygenase-2 inhib-
itor, delayed the progression of B16 tumors in mice through
mechanisms involving expansion of IFNg-producing CD8þ T
cells (44). Noteworthy, our results were achieved taking advan-
tage of OVA as a tumor antigen of B16-OVA. However, future
research of the effect of T3-treated DCs in the presence of
recombinant native-speciﬁc tumor peptides should be con-
ducted in B16 as well as in other tumor models.
The majority of clinical trials involving DC-based vaccination
uses a cocktail of proinﬂammatory cytokines, including TNF,
Figure 6.
Vaccination with T3-stimulated DCs
augments the frequency of
intratumoral CD8þ T cells and
increases IFNg production. Animals
were treated as described in Fig. 5A,
and sacriﬁced on day 27. A, tumor-
inﬁltrating cells were determined by
ﬂow cytometry. Numbers represent
the percentage of cells in each
quadrant. B, IFNg production by
splenic T cells from tumor-bearing
mice determined by ELISA. C, the
frequency of IFNg-secreting CD4þ
and CD8þ splenic T cells was
determined by ﬂow cytometry. The
numbers in each quadrant represent
the percentage of total cells
expressing CD4 or CD8 and IFNg . Data
are expressed as mean  SD. Results
are from a representative of three
experiments (n ¼ 5).  , P < 0.001 vs.
basal DCþOVAþT3;  , P < 0.001 vs.
stimulated DCþOVA.
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IL1b, IL6, and PGE2 (45). Moreover, other authors explored the
use of CD40L (46) and Toll-like receptor agonists that differen-
tially stimulate systemic and local innate immune responses (47).
Taken together, our previous (15, 16) and current ﬁndings pro-
pose the emergence of T3 as an adjuvant alternative that educates
DCs for stimulating antigen-speciﬁc effective T-cell responses in
cancer settings. Moreover, given its physiologic origin, T3 may
exhibit advantages over other artiﬁcial adjuvants, which could
display higher toxicity.
Importantly, our study highlights an alternative mechanism by
which thyroid hormone inﬂuence tumor growth inhibition in
addition to other tumor suppressor roles of TRb1 (48). In this
sense, TRbPV mice develop follicular thyroid carcinoma and
mutated TRs associate with several human cancers, including
liver, kidney, pituitary, and thyroid tumors (7). On the other
hand, diminished expression of TRbmRNA has been implicated
in the carcinogenesis of papillary thyroid carcinomas, kidney, and
breast cancers (48). Hence, reduced DC immunogenicity docu-
mented in TRbPVmice and augmented cytotoxic T-cell responses
triggered by T3-conditioned DCs may also contribute to tumor
development and progression observed under TRb deﬁciency. In
contrast, other studies support the concept that WT TRs can
enhance carcinogenesis, suggesting that TRs could play a dual
role in carcinogenesis (49). Because TR actions are complex,
tissue-restricted and stage-speciﬁc, aberrant expression of the
various TR isoforms might have divergent roles in diverse tumor
types and/or at different stages of tumor development (49). Our
ﬁndings suggest a novelmechanismbywhich the T3-TRb complex
inﬂuences antitumor response by bolstering DC-mediated T-cell
activation during tumor growth. Interestingly, although the
experiments shown here were performed at T3 physiologic con-
centrations, further work should be aimed at elucidating the
impact of different thyroid states (hypothyroid, euthyroid, or
hyperthyroid) in DC functionality in vivo and antitumor
responses.
In summary, our ﬁndings emphasize the physiologic roles of
the thyroid hormone in the development of antitumor response
and highlight the use of T3-conditioned DCs as an alternative
approach to potentiate T-cell–mediated tumor immunity.
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